帶狀皰疹后遺神經(jīng)痛物理治療-2016英文文獻(xiàn)

1、postherpetic neuralgia treatment，physiotherapy2016.1.19，70Items: 70Select item 256002581.Int J Dermatol. 2015 Apr;54(4):476-80. doi: 10.1111/ijd.12385. Epub 2015 Jan 20.Transcutaneous electrical nerve stimulation for chronic post-herpetic neuralgia.Ing MR1, Hellreich PD, Johnson DW, Chen JJ.Author i

2、nformation1Department of Surgery, University of Hawaii School of Medicine, Honolulu, HI, USA.AbstractPostherpetic neuralgia remains a therapeutic challenge for the clinician. Many modalities have been utilized with limited success. In this pilot randomized study of patients who were refractory to pr

3、evious medicinal treatment, the patients were treated with transcutaneous nerve stimulation with a biofeedback capability. After every two treatments with the sham and true device, the patients were required to fill out a standard neuropathic pain scale score. The patients were allowed to select the

4、 other device after three consecutive treatments if they felt an inadequate decrease in their pain. The true device was chosen over the sham device by all patients. The majority of these patients treated by the true device reported a statistically significant decrease in pain scores (P < 0.001).

5、Further investigation of this Food and Drug Administration, class 2 accepted, electronic device for relief of pain is warranted for patients with a history of recalcitrant postherpetic neuralgia. © 2015 The International Society of Dermatology.PMID:25600258PubMed - indexed for MEDLINE Similar a

6、rticlesPublication Types, MeSH Terms, Grant SupportPublication TypesRandomized Controlled TrialResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tMeSH TermsSelect item 254592522.Clin Neurol Neurosurg. 2014 Dec;127:101-5. doi: 10.1016/j.clineuro.2014.10.009. Epub 2014 Oct 23.Peri

7、pheral field stimulation for thoracic post herpetic neuropathic pain.Zibly Z1, Sharma M1, Shaw A1, Deogaonkar M2.Author information1Department of Neurosurgery, Center of Neuromodulation, Wexner Medical Center, The Ohio State University, Columbus, USA.2Department of Neurosurgery, Center of Neuromodul

8、ation, Wexner Medical Center, The Ohio State University, Columbus, USA. Electronic address: Milind.D.AbstractOBJECTIVE: Post herpetic neuralgia is a chronic, debilitating pain with very few management options and is often refractory to treatment. We present our experience with a se

9、ries of 4 patients who underwent subcutaneous peripheral field stimulation for treatment of thoracic post herpetic neuropathic pain.METHODS: Four patients with intractable thoracic post herpetic neuropathic pain were operated after maximum medical treatment and a neuropsychological evaluation. Multi

10、ple percutaneous electrodes were placed in the subcutaneous plane in the region of pain for a 7-day trial. Following a successful trial (more than 50% reduction of pain), the electrodes were then internalized and attached to a pulse generator. Visual analog scores (VAS) were studied during the preop

11、erative, immediate postoperative and last follow-up visits. Long-term treatment results were determined by retrospective review of medical records. Average follow-up period was 28.2 months.RESULTS: All 4 patients showed persistent improvement in their VAS pain scores with an average improvement of m

12、ore than 75%. There were no treatment failures and no complication requiring re-operation was reported.CONCLUSION: Peripheral field stimulation for the treatment of post herpetic neuropathic pain is a safe and effective method for pain relief for an extremely complex problem with very few solutions.

13、 Patient selection and proper lead placement is most important for the success of treatment.Copyright © 2014 Elsevier B.V. All rights reserved.KEYWORDS: Neuromodulation; Neuropathic pain; Peripheral field stimulation; Post-herpetic; ThoracicPMID:25459252PubMed - indexed for MEDLINE Similar arti

14、clesMeSH Terms3.Minerva Med. 2014 Dec;105(6):515-27.Topical pharmacologic approach with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain.Article in ItalianProvinciali L1, Lattanzi S, Chiarlone R, Fogliardi A, Intelligente F, Irace C, Lanzilotta M, Palomba R, Storelli E,

15、Zampi M.Author information1Clinica Neurologica, Dipartimento di Medicina Sperimentale e Clinica, Università Politecnica delle Marche Ancona, Italia - vincialiunivpm.it.AbstractThe treatment of neuropathic pain is a medical challenge. The responsiveness to the different classes of drugs is

16、often unsatisfactory and frequently associated to a wide range of side effects. International guidelines suggest for the "localized" neuropathic pain the topical treatment with 5% lidocaine medicated plaster, alone or associated to systemic drugs, as the first choice since its favorable ef

17、ficacy and tolerability profile. Many clinical experiences support the rationale for using 5% lidocaine medicated plaster in different kinds of localized neuropathic pain, such as postherpetic and trigeminal neuralgia, compressive syndromes, painful diabetic polyneuropathy and pain secondary to trau

18、ma or surgical interventions. This paper reports a series of clinical cases whose heterogeneity suggests the wide burden of applicability of the topical 5% lidocaine, either alone and associated to systemic drugs. All the described conditions were characterized by a highly intense pain, not adequate

19、ly controlled by actual medications, which improved after the use of topical lidocaine. The good response to lidocaine allowed the reduction, of even the withdrawal, of concurrent drugs and improved the patients' quality of life. PMID:25392960PubMed - indexed for MEDLINE Similar articlesPublicat

20、ion Types, MeSH Terms, SubstancesPublication TypesCase ReportsEnglish AbstractSelect item 251128894.Neuromodulation. 2014 Aug;17(6):515-50; discussion 550. doi: 10.1111/ner.12208.The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pai

21、n and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee.Deer TR1, Mekhail N, Provenzano D, Pope J, Krames E, Leong M, Levy RM, Abejon D, Buchser E, Burton A, Buvanendran A, Candido K, Caraway D, Cousins M, DeJongste M, Diwan S, Eldabe S, Gatzinsky K, Foreman RD, Hayek S, Kim

22、 P, Kinfe T, Kloth D, Kumar K, Rizvi S, Lad SP, Liem L, Linderoth B, Mackey S, McDowell G, McRoberts P, Poree L, Prager J, Raso L, Rauck R, Russo M, Simpson B, Slavin K, Staats P, Stanton-Hicks M, Verrills P, Wellington J, Williams K, North R; Neuromodulation Appropriateness Consensus Committee.Auth

23、or information1Center for Pain Relief, Charleston, WV, USA.AbstractINTRODUCTION: The Neuromodulation Appropriateness Consensus Committee (NACC) of the International Neuromodulation Society (INS) evaluated evidence regarding the safety and efficacy of neurostimulation to treat chronic pain, chronic c

24、ritical limb ischemia, and refractory angina and recommended appropriate clinical applications.METHODS: The NACC used literature reviews, expert opinion, clinical experience, and individual research. Authors consulted the Practice Parameters for the Use of Spinal Cord Stimulation in the Treatment of

25、 Neuropathic Pain (2006), systematic reviews (1984 to 2013), and prospective and randomized controlled trials (2005 to 2013) identified through PubMed, EMBASE, and Google Scholar.RESULTS: Neurostimulation is relatively safe because of its minimally invasive and reversible characteristics. Comparison

26、 with medical management is difficult, as patients considered for neurostimulation have failed conservative management. Unlike alternative therapies, neurostimulation is not associated with medication-related side effects and has enduring effect. Device-related complications are not uncommon; howeve

27、r, the incidence is becoming less frequent as technology progresses and surgical skills improve. Randomized controlled studies support the efficacy of spinal cord stimulation in treating failed back surgery syndrome and complex regional pain syndrome. Similar studies of neurostimulation for peripher

28、al neuropathic pain, postamputation pain, postherpetic neuralgia, and other causes of nerve injury are needed. International guidelines recommend spinal cord stimulation to treat refractory angina; other indications, such as congestive heart failure, are being investigated.CONCLUSIONS: Appropriate n

29、eurostimulation is safe and effective in some chronic pain conditions. Technological refinements and clinical evidence will continue to expand its use. The NACC seeks to facilitate the efficacy and safety of neurostimulation.© 2014 International Neuromodulation Society.KEYWORDS: Angina pectoris

30、; Reynaud's syndrome; chronic pain; complex regional pain syndrome; failed back surgery syndrome; high-frequency electrical stimulation; ischemic pain; neuropathic pain; nociceptive pain; phantom limb pain; postherpetic neuralgia; spinal cord stimulationPMID:25112889PubMed - indexed for MEDLINE

31、Similar articlesPublication Types, MeSH Terms, SubstancesPublication TypesComparative StudyConsensus Development ConferencePractice GuidelineResearch Support, Non-U.S. Gov'tSelect item 245957055.Curr Pain Headache Rep. 2014 Apr;18(4):406. doi: 10.1007/s11916-014-0406-7.Spinal cord stimulation fo

32、r intractable chronic pain.Kapural L1.Author information1Carolinas Pain Institute at Brookstown, Wake Forest Baptist Health, Winston-Salem NC, 605 Cotton Street, Winston Salem, NC, 27103, USA, .AbstractSpinal cord stimulation (SCS) is minimally invasive and reversible therapy f

33、or treatment of severe, otherwise nonresponsive chronic pain. Such approach is relatively safe, with very few side-effects, not addictive, and provides enduring therapeutic response. A number of clinical studies support the efficacy of spinal cord stimulation in treating failed back surgery syndrome

34、 and complex regional pain syndrome, as well as peripheral neuropathic pain, postamputation pain, postherpetic neuralgia, root and spinal cord injury pain. In addition, neurostimulation has been used to treat refractory angina, chronic abdominal pain, peripheral vascular disease, and vaso-occlusive

35、syndromes. Clinical use of spinal cord stimulation is expanding at very fast pace, and new technological modalities in SCS will provide a new clinical evidence with likely better pain control.PMID:24595705PubMed - indexed for MEDLINE Similar articlesPublication Types, MeSH TermsPublication TypesRevi

36、ewSelect item 241969716.Am J Phys Med Rehabil. 2014 Apr;93(4):287-98. doi: 10.1097/PHM.0000000000000002.Transcutaneous electrical nerve stimulation in combination with cobalamin injection for postherpetic neuralgia: a single-center randomized controlled trial.Xu G1, Xú G, Feng Y, Tang WZ, Lv ZW

37、.Author information1From the Department of Rehabilitation Medicine (GX, GX, YF, WZT) and Department of Nuclear Medicine (ZWL), Tenth People's Hospital Affiliated Tongji University, Shanghai, China.AbstractOBJECTIVE: The aim of this study was to explore the efficacy of transcutaneous electrical n

38、erve stimulation (TENS) with locally injected cobalamin in relieving pain and improving activities of daily living in patients with postherpetic neuralgia.DESIGN: Ninety patients (50 yrs old) with postherpetic neuralgia with a pain score of 4 or greater were randomized to receive TENS and local inje

39、ctions of cobalamin or lidocaine or a combination of cobalamin and lidocaine for 8 wks. Treatment efficacy was assessed on the basis of worst pain severity, global impression of change, activities of daily living, and quality-of-life.RESULTS: Time × group interaction, group differences, and tim

40、e effect on worst pain at each follow-up point were statistically significant (P < 0.05) among the groups. In the group receiving TENS and local injection of cobalamin and in the group receiving TENS with a combination of cobalamin and lidocaine, the mean ± SD pain scores were 4.0 ± 1.4

41、 and 4.1 ± 1.2 at endpoint, 28 and 26 patients achieved pain reduction of 30% or greater, and 14 and 10 perceived worst pain of 3 or less, respectively. The activities of daily living and quality-of-life data at the study endpoint showed significant benefits in the group receiving TENS and loca

42、l injection of cobalamin and in the group receiving TENS and a combination of cobalamin and lidocaine (P < 0.05). In the group receiving TENS and local injection of lidocaine, the mean ± SD pain score was 6.1 ± 1.2 at the endpoint relative to baseline (P < 0.05), and only six patient

43、s achieved pain reduction of 30% or greater.CONCLUSIONS: TENS in combination with local cobalamin injection has a significant analgesic effect.PMID:24196971PubMed - indexed for MEDLINE Similar articlesPublication Types, MeSH Terms, SubstancesPublication TypesRandomized Controlled TrialSelect item 23

44、5519377.Mol Pain. 2013 Apr 3;9:18. doi: 10.1186/1744-8069-9-18.Electroacupuncture improves thermal and mechanical sensitivities in a rat model of postherpetic neuralgia.Wu CH1, Lv ZT, Zhao Y, Gao Y, Li JQ, Gao F, Meng XF, Tian B, Shi J, Pan HL, Li M.Author information1Department of Neurobiology, Sch

45、ool of Basic Medicine, Tongji Medical College of Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, 430030, PR China.AbstractBACKGROUND: Electroacupuncture (EA) is effective in relieving pain in patients with postherpetic neuralgia (PHN). However, the mechanism underlying the th

46、erapeutic effect of EA in PHN is still unclear. Systemic injection of resiniferatoxin (RTX), an ultrapotent analog of TRPV1 agonist, in adult rats can reproduce the clinical symptoms of PHN by ablating TRPV1-expressing sensory neurons. In this study, we determined the beneficial effect of EA and the

47、 potential mechanisms in this rat model of PHN.METHODS: PHN was induced in rats by a single injection of RTX. Thermal hyperalgesia was tested with a radiant heat stimulus, and mechanical allodynia was quantified with von Frey filaments. TRPV1 receptors were shown by using immunofluorescence labeling

48、. The ultrastructural changes of the sciatic nerve were assessed by electron microscopic examination. The sprouting of myelinated primary afferent terminals into the spinal dorsal horn was mapped by using the transganglionic tracer cholera toxin B-subunit (CTB).RESULTS: RTX injection diminished ther

49、mal sensitivity and gradually induced tactile allodynia within 3 weeks. EA applied to GB30 and GB34 at 2 and 15 Hz, but not 100 Hz, significantly increased the thermal sensitivity 4 weeks after treatment and decreased the tactile allodynia 2 weeks after treatment in RTX-treated rats. EA treatment at

50、 2 and 15 Hz recovered the loss of TRPV1-positive dorsal root ganglion neurons and their central terminals of afferent fibers in the spinal superficial dorsal horn of RTX-treated rats. Moreover, EA significantly reduced the loss of unmyelinated fibers and the damage of the myelinated nerve fibers of

51、 RTX-treated rats. Furthermore, EA at 2 and 15 Hz inhibited the sprouting of myelinated primary afferent terminals into the spinal lamina II of RTX-treated rats.CONCLUSIONS: EA treatment improves thermal perception by recovering TRPV1-positive sensory neurons and nerve terminals damaged by RTX. EA A

52、lso reduces RTX-induced tactile allodynia by attenuating the damage of myelinated afferent nerves and their abnormal sprouting into the spinal lamina II. Our study provides new information about the mechanisms of the therapeutic actions of EA in the treatment of PHN.PMID:23551937PubMed - indexed for

53、 MEDLINE PMCID:PMC3626545Free PMC ArticleSimilar articlesPublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tSelect item 235427558.Neuropsychopharmacol Hung. 2013 Mar;15(1):13-7.New data for the pathomechanism of neuropathic pain: therapeutic evidences.Artic

54、le in HungarianTajti J1, Szok D, Vécsei L.Author information1Neurológiai Klinika, Szegedi Tudományegyetem, Szeged, Hungary. tajti.janosmed.u-szeged.huAbstractThe present work is based on literature data from PubMed. Neuropathic pain is caused by a lesion or disease of the somatosensor

55、y system. Peripheral and central sensitization play a crucial role in its pathomechanism. The clinical symptoms are mainly characterized by burning and throbbing pain and sensory disturbances like hyperalgesia and allodynia. Therapeutic recommendations are antidepressants, antiepileptics, opioids an

56、d neuro-stimulation methods.PMID:23542755PubMed - indexed for MEDLINE Free full textSimilar articlesPublication Types, MeSH Terms, SubstancesPublication TypesEnglish AbstractReviewSelect item 233405309.Pain Physician. 2013 Jan;16(1):15-25.Efficacy of pulsed radiofrequency in the treatment of thoraci

57、c postherpetic neuralgia from the angulus costae: a randomized, double-blinded, controlled trial.Ke M1, Yinghui F, Yi J, Xeuhua H, Xiaoming L, Zhijun C, Chao H, Yingwei W.Author information1Department of Anesthesiology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 2009

58、2, China.AbstractBACKGROUND: Postherpetic neuralgia (PHN) is often refractory to existing treatments. Pulsed radiofrequency (PRF) is known to be effective for treating neuropathic pain. In common, the targets of PRF treatment were the segmental dorsal root ganglion (DRG) neurons responsible for the pain. A potential complication that can occasionally occur with PRF treatment is damage to the adjacent tissue and organ. The effectiveness of the angulus costae as a puncture site for PRF has not been tested in thoracic PHN treatment.OBJECTIVE: The goal of this study was to investigate the t